The Startup Freezing Humans For Tomorrow - Interview with Dr Emil Kendziorra, CEO of Tomorrow.bio

Why It Matters

Tomorrow.bio demonstrates how a high‑risk, mission‑driven biotech can attract substantial capital while shaping the emerging longevity market, forcing investors and regulators to confront the future of life extension.

Key Takeaways

• Tomorrow.bio offers cryopreservation for humans and pets in Europe.
• Founder Emil Kendziora sees longevity as lifelong mission, not exit.
• Company raised €5 million, aiming for 100k clients to become viable.
• Cryopreservation currently a business model, revival technology still unproven.
• Market growth hinges on future medical breakthroughs and regulatory acceptance.

Summary

The EU Startups podcast featured an interview with Dr. Emil Kendziora, CEO of Tomorrow.bio, a European startup that provides cryopreservation services for both humans and pets. The conversation explored the company’s mission, funding, and the broader context of longevity research.

Kendziora, a physician‑turned‑entrepreneur, described his lifelong drive to extend human life and positioned Tomorrow.bio as his “life’s work.” The firm recently closed a €5 million round and aims to enroll roughly 100,000 clients, a threshold that would make the business economically sustainable even before revival technology is proven.

Notable moments included Kendziora’s declaration that he will never start another company and his refusal to sell the business for a large offer, underscoring the mission‑first ethos. He also clarified that current cryopreservation is akin to sci‑fi stasis—useful for terminal patients now, but revival depends on future medical breakthroughs.

The interview highlights a nascent but potentially massive market at the intersection of biotech, finance, and ethics. Investors are watching for regulatory clarity and scientific advances that could turn a speculative service into a mainstream longevity solution.

Original Description

Join us for a deep-dive conversation with Dr Emil Kendziorra, CEO of Tomorrow.bio, as we explore the cutting edge of cryopreservation and medical biostasis.

Dr Kendziorra, who began his career in cancer research with a summa cum laude degree from the University of Göttingen, shares his remarkable journey from academic science to entrepreneurship, and ultimately to founding Tomorrow.bio - a company he considers his life’s work.

In this interview, he discusses the motivations behind his pivot from traditional longevity research to the frontier of cryomedicine, the operational and emotional lessons learned from cryopreserving over 20 human patients and 10 pets, and his vision for making this technology more accessible in the future.

Tomorrow.bio stands as Europe’s fastest-growing cryopreservation company, with over 800 members across 200+ cities and 45+ countries. The company offers both whole-body cryopreservation and brain-only preservation, using a transparent pricing model designed for long-term value.

With a recent €5 million Seed round and a mission to advance medical biostasis, Emil discusses the unique challenges and opportunities of operating in this space, the ethical considerations of a technology that may not achieve revival for decades, and his long-term vision for the field.

Key Points

- The pivotal moment when Emil decided to dedicate his life to cryopreservation and biostasis, leaving behind a career in cancer research.

- The necessity of a European-based cryopreservation organisation and what was missing before Tomorrow.bio entered the field.

- A detailed explanation of the cryopreservation process, from sign-up and stabilization to long-term storage in liquid nitrogen.

- Addressing the gap between preservation and revival, and the importance of honest communication with members about the current limitations.

- The operational and emotional lessons learned from cryopreserving the first 20 human patients and 10 pets.